In a Push to Limit Use of Glucocorticoids, US and EU5 Rheumatologists are Increasingly Turning to GSK’s Benlysta and AstraZeneca’s Saphnelo for the Treatment of Moderate-to-Severe Systemic Lupus Erythematosus, According to Spherix Global Insights
Despite overall biologic growth in both geographies, use of advanced systemic treatments in the US outpaces the EU5. EXTON, PA., October 4, 2023 – Prior to the initial approval of Benlysta in 2011, systemic lupus erythematosus (SLE) patients and prescribers had limited options for the management of this debilitating disease, often relying on symptom management […]
Consecutive Use of TNF-Inhibitors for the Treatment of Psoriatic Arthritis at Lowest Point Recorded, as Use of Biologics with Alternate Mechanisms of Actions Continue to Grow, According to Spherix Global Insights
Analysis of 1,025 recently switched PsA patients reveals second- or later-line usage of IL-17, IL-23, and JAK inhibitors growing in popularity. Exton PA, October 3, 2023 — US rheumatologists (n=204) report nearly two-thirds of their psoriatic arthritis (PsA) patients are undergoing treatment with advanced systemic therapies. What’s more, one-third of these patients have switched therapies […]
Amgen’s Amjevita Remains the Frontrunner in the US Adalimumab Biosimilars Market, Despite Increased Competition, According to Spherix Global Insights.
Boehringer Ingelheim’s Cyltezo has a slight competitive edge over other concurrent biosimilar launches on certain key performance metrics, though prescriber future projections show little differentiation in use among the recent entrants. Exton, PA, September 14, 2023 — This summer ushered in the highly anticipated introduction of a multitude of additional adalimumab biosimilars to the dynamic […]
Market Access Issues Hindering Specialists’ Use of Advanced Systemics in Lupus Nephritis
According to Spherix Global Insights, US Rheumatologists are taking increasing ownership over lupus nephritis (LN) patient management, yet they are more likely than nephrologists to express frustrations with payers’ restriction of LN drugs. EXTON, Pa., July 27, 2023 — While the approvals of GSK’s Benlysta (belimumab) and Aurinia’s Lupkynis (voclosporin) have provided rheumatologists and nephrologists […]
Patients with Moderate-to-Severe SLE are Increasingly Being Treated with Biologic Therapies Such as GSK’s Benlysta and AstraZeneca’s Saphnelo, According to Spherix Global Insights
In the third annual patient chart analysis, major treatment shifts in biologic use and average daily steroid dose were observed. EXTON, Pa., June 15, 2023 — Systemic lupus erythematosus (SLE) patients present significant challenges in management, given the complexity of the condition and few effective treatment options available. However, recently approved lupus therapies and a […]
New Research on Emerging Cutaneous Lupus Erythematosus (CLE) Market Reveals Vast Potential for Pipeline Agents, According to Spherix Global Insights
U.S. specialists’ lack of satisfaction with current treatment options in cutaneous and discoid lupus paves the way for advanced pharmacological agents to disrupt the market EXTON, Pa., May 8, 2023 /PRNewswire/ — According to the Lupus Foundation of America, approximately two-thirds of people with the autoimmune condition systemic lupus erythematosus (SLE) will develop some type […]
Spherix Global Insights: Despite High Awareness, Provider Comfort With Adalimumab Biosimilars Is Low
April 3, 2023 Skylar Jeremias Although rheumatologists, dermatologists, and gastroenterologists rated their awareness of adalimumab biosimilars as high, a significant proportion of each group reported that they were not confident prescribing a biosimilar over the originator. Although rheumatologists, dermatologists, and gastroenterologists rated their awareness of adalimumab biosimilars as high, a significant proportion of each group […]
Introduction of AstraZeneca’s Saphnelo (anifrolumab) has Expanded the Use of Biologic Agents in the Treatment of Systemic Lupus Erythematosus (SLE), Resulting in Gains for GSK’s Benlysta (belimumab) as Well, According to Spherix Global Insights
Latest Saphnelo launch tracking data from Spherix showcases rheumatologists’ shifting perception on the drug’s steroid-sparing capabilities yet highlights access barriers hindering use. EXTON, Pa., February 22, 2023 – Rheumatologists have long struggled to effectively treat patients with systemic lupus erythematosus (SLE) given the wide heterogeneity of the disease and few effective treatment options. However, after […]
Major Shifts in Management of Patients with Lupus Nephritis Spurred by Availability of Aurinia Pharmaceutical’s Lupkynis and GSK’s Benlysta, According to Spherix Global Insights
Latest patient-level data analysis by Spherix Global Insights showcases year over year shifts in nephrology and rheumatology practice patterns alongside strong appetite for new LN pipeline drugs. EXTON, Pa., January 20, 2023 /PRNewswire/ — With the approvals of GlaxoSmithKline’s Benlysta (belimumab) in lupus nephritis (LN) at the end of 2020 and Aurinia’s Lupkynis (voclosporin) at […]
Long-Term Psoriatic Arthritis Data for AbbVie’s Skyrizi Likely to Impact Future IL-23 Preference, Spherix Global Insights Reports
Newly released data may provide a competitive edge over in-class competitor, Janssen’s Tremfya EXTON, Pa., December 21, 2022 /PRNewswire/ — Spherix Global Insights, a leading provider of market research, business intelligence, and advisory services to the global life sciences industry, has been tracking the evolution of the US psoriatic arthritis (PsA) market for seven years, including […]
